Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release d...
Foresee Pharmaceuticals reported revenue of 431.27 million TWD for fiscal year 2025, up 3.0% from fiscal year 2024, and net income of -883.15 million TWD. United States was its largest region in fiscal year 2025, with 63% of revenue.
Figures from company filings; latest fiscal year ended December 31, 2025.
No profile data available.